Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.…
Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
Abrdn Life Sciences Investors (NYSE: HQL) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Asset Management industry, part of the Financial Services sector.
The shares were at 15.38 USD on 20 November 2026, down 1.4% over 52 weeks. Its 52-week range is 15.36 USD to 22.67 USD, and it trades at the bottom of that range.
At a market capitalisation of 467.68M USD, it trades at 2.3 times trailing earnings. The median trailing P/E of its 18 largest Asset Management peers is 14.8, a discount of 84% for HQL.
Abrdn Life Sciences Investors reports return on equity of 16.7%, an operating margin of -428.4% and revenue down 60.8% year over year.
It holds more cash than debt, a net cash position of 851.60K USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.